share
  • facebook
  • twitter
  • linked in
  • google+
back top
The Biologic Association 2020

Scientific Agenda

Scientific Agenda

Biologic Association Summit & Think Tank

Session Room Think Tank & Summit: Grand Pacific Ballroom (Westin Conference Center)
Session Room Ultrasound and Orthobiologics Skills Workshop: Cardiff Room (Westin Conference Center)

Final Programme BA Summit & ISMF Conference (PDF, 2.5 MB)

5 February (Wednesday)

  • 10:00 - 18:30
    Registration Think Tank
  • 12:30 - 19:00
    Biologic Association Think Tank (upon invitation only)
    The Think Tank format will be similar to the television show: “Shark Tank".  Presenters (“contestants”) will be industry or academic researchers with new orthobiologic ideas, products, applications, etc. They will appear before a panel of judges similar to those on Shark Tank, only these judges have special expertise in orthopedics/OrthoBiologics. After the judging panel has completed their questions and suggestions, the presenters will take question from a panel of industry reporters/analysts and then from the floor. The session will end with recommendations from the Judges who will also score the presenters to allow for a “winner” at the conclusion of the day. Judges/Sharks: Scott Bruder, Laurence Higgins, Nicholas Pachuda, Christopher Shen Reporters/Analysts: Kim French, Sharon O'Reilly, Robin Young, Patrick Duffey
  • 12:30 - 14:00
    Session 1
    • 12:30 - 13:00
      Kimera: Chondrogenic Exosome Hydrogel for Articular Cartilage Regeneration
      Kimera Labs is developing an exosome-based biopharmaceutical solution for the regeneration of articular cartilage damaged by osteoarthritis. Building on our industry-leading experience in preparation and isolation of perinatal mesenchymal stem cell-derived (MSC) exosomes, Kimera is bioengineering chondrogenic MSC exosomes that will not only improve inflammation and pain, but also prevent proteoglycan degradation, sustain chondrocyte viability and stimulate chondrocyte progenitor cell proliferation, migration and synthesis of normal articular cartilage. These chondrogenic MSC exosomes will be embedded in a biocompatible, injectable, composite hydrogel matrix that localizes the exosomes to the damaged joint and enables the extended release and sustained viability of the exosomes to mimic the effects of autologous progenitor cells, which have demonstrated the capacity to regenerate articular cartilage, but with a completely off-the-shelf solution.
    • 13:00 - 13:30
      Organogenesis: Amniotic Suspension Allograft Improves Pain and Function in Osteoarthritis – The Evidence
      ReNu is an amniotic suspension allograft developed by Organogenesis. ReNu is a single intra-articular injection and is composed of cells from the amniotic fluid and micronized amniotic membrane, which contains regenerative and anti-inflammatory cytokines and growth factors. Preclinical data has shown improvements in pain relief and weight bearing differences following treatment with ReNu in two animal models. In a randomized multicenter clinical study, treatment with ReNu resulted in improvements in pain and function out to 12 months compared to controls.
    • 13:30 - 14:00
      Samumed: Lorecivivint: A First-in-Class, Disease-Modifying Drug Candidate for Knee Osteoarthritis.
      Lorecivivint is a small-molecule CLK/DYRK inhibitor that modulates the Wnt pathway and is in development by Samumed as a potential disease-modifying drug for osteoarthritis (DMOAD), delivered by intra-articular injection. Preclinical data suggest that Lorecivivint has a dual mechanism of action with three effects on joint health: generation of cartilage, slowing of cartilage breakdown, and reduction of inflammation. Lorecivivint is currently undergoing Phase 3, randomized controlled trials.
  • 14:00 - 14:30
    Break
  • 14:30 - 16:00
    Session 2
    • 14:30 - 15:00
      Lipogems: Micro-fragmented Adipose Tissue: Basic Science and Clinical Evidence
      A clear clinical need has emerged to offer alternative solutions to patients falling into the Orthopedic treatment gap: individuals that have failed conservative therapies but are not yet ready, or cannot undergo major invasive surgery. Although multiple Biologic solutions have been developed to target this patient population, the evidence supporting their clinical efficacy is lacking.  This presentation will provide an in-depth overview of the basic science underlying the potential MOA of Lipogems micro-fragmented fat tissue (MFat), and discuss the clinical evidence reflecting safety and efficacy in this patient population.
    • 15:00 - 15:30
      Orthopedic Stem Cell Research Lab, Regenerative Medicine Institute, Cedars-Sinai: Identification of Cell and Protein Biomarkers in PRP to Improve Individual Pain Outcomes in Knee OA
      We aim to identify cell and protein biomarkers in platelet-rich plasma (PRP) that correlate with reduced knee osteoarthritis (OA)-associated pain levels post-PRP treatment to allow for prediction of PRP therapy efficacy. This study will provide a thorough analysis of PRP cell and protein biomarker composition and its effect on clinical outcomes and thus will allow to identify the main contributors to PRP’s efficacy. These findings will allow to define new standards of PRP composition, leading to higher success rates in PRP therapy for knee OA.
    • 15:30 - 16:00
      Regenacell Therapy: Marrow Cellution Device And The CellFUSE - Bone Graft Substitute
      Doctor Chabot will present in regards to the Marrow Cellution™ bone marrow aspiration device technology (innovative and proven method to aspirate bone marrow and obtain high yields of regenerative cells) as well as the recently released bone graft substitute CellFUSE™ a hypercrosslinked carbohydrate polymer (HCCP) for the repair of critical sized bone defects. When used in combination by a surgeon these two innovative products provide Regenerative Cells, Organic Signaling and a Scaffold designed to promote bone fusion. Endocellutions and Regenacell are privately held small business concerns that develop and market novel, innovative medical devices designed to maximize the potential of autologous regenerative medicine.
  • 16:00 - 16:30
    Break
  • 16:30 - 18:00
    Session 3
    • 16:30 - 17:00
      Keck School of Medicine of USC: Evaluation of Engraftable Human Pluripotent Stem Cell-Derived Chondrocytes in a Long-Term Preclinical Pig Model of Focal Cartilage Injury
      Our group of scientists and clinicians has been continuously funded by the California Institute of Regenerative Medicine (CIRM) to develop a first-in class pluripotent stem cell-based therapy for focal articular cartilage lesions. Plurocart® is an off-the-shelf allogeneic cryopreserved bioreactor-made biological implant composed of highly purified human stem cell-derived immature articular chondrocytes. Detailed molecular, cellular and functional characteristics of the Plurocart® technology will be presented.
    • 17:00 - 17:30
      Bioventus: Preclinical Characterization and Clinical Development Plans for PTP-001, a Novel Human Tissue Biologic in Development For The Treatment of Osteoarthritis.
      To date, all attempts to develop disease-modifying therapies for OA have failed, principally due to lack of clinical efficacy or safety issues. Such treatments have generally focused on modulation of a single target (e.g. a specific cytokine or enzyme/protease) whereas OA is a complex, mutifactorial disease process. PTP-001 is an effective tissue-derived treatment, with an inherent multi-modal MOA that can impact a number of pathologic pathways (including pain and tissue damage) which contribute to OA. This presentation will focus on the evidence and the development plans for PTP-001 as a regulated biologic product, in concordance with FDA guidance, as a novel approach for the treatment of OA and other musculoskeletal conditions.
    • 17:30 - 18:00
      Biorez: The First Look at BioBrace™, a New, Fully Resorbable, Bioactive Tissue Regeneration Scaffold For The Repair of Ligament and Tendons
      Biorez is dedicated to helping patients return to full activity sooner and safer following debilitating ligament and tendon injuries.  We have developed the BioBrace™ scaffold, a new implant technology to reinforce tendon and ligament repairs and to facilitate tissue regeneration. Through our proprietary open porous architecture, and use of biomaterials, the BioBrace™ has been engineered to provide a high degree of bio-inductivity to promote rapid tissue regeneration, a biomechanical profile to reinforce repairs throughout the full healing profile, and full absorption overtime to fully restore the anatomy to its normal state. In addition, the BioBrace can be utilized as a carrier for orthobiologics, holding over 600% its weight with any biologic fluid for a more localized delivery. Early pre-clinical work suggest that BioBrace will deliver on the promise of a superior tissue scaffold to accelerate rehabilitation, regenerate organized tissue, and improve overall outcomes.
  • 18:00 - 19:00
    Closing & Happy Hour
    For Think Tank participants only.

6 February (Thursday)

7 February (Friday)